Stockscreener 앱 받기
0.2724
1.27%
-0.0035
시간 외 거래:
29.72
29.45
+10,810%
Relmada Therapeutics Inc 주식(RLMD)의 최신 뉴스
Relmada outlines plans for NDV-01 Phase 2 results presentation and sepranolone development - MSN
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2024 Earnings Call Transcript - Insider Monkey
Relmada Therapeutics: Strategic Acquisitions and Pipeline Progress - TipRanks
Relmada Therapeutics pivots from psilocybin to cancer, neurological disorders - Green Market Report
Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights: Strategic Acquisitions and ... - Yahoo Finance
Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights - GuruFocus.com
Relmada Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks
Earnings call transcript: Relmada Therapeutics Q4 2024 sees improved EPS By Investing.com - Investing.com South Africa
Earnings call transcript: Relmada Therapeutics Q4 2024 sees improved EPS - Investing.com India
RELMADA THERAPEUTICS Earnings Results: $RLMD Reports Quarterly Earnings - Nasdaq
Relmada Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - The Manila Times
Relmada Cuts Losses by 25%: Key Pipeline Programs Hit Critical Phase in 2025 - Stock Titan
Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights: Strategic Acquisitions and ... By GuruFocus - Investing.com Canada
Relmada Therapeutics Inc -On March 24, Enters Exclusive License Agreement With Trigone PharmaSEC Filing - MarketScreener
Insights Ahead: Relmada Therapeutics's Quarterly Earnings - Benzinga
Mizuho maintains Relmada stock neutral with $1.00 target By Investing.com - Investing.com Canada
Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025 - Quantisnow
Mizuho maintains Relmada stock neutral with $1.00 target - Investing.com India
Mizuho Reiterates Neutral Rating on Relmada Therapeutics Inc (RLMD) - StreetInsider.com
Relmada secures exclusive license for potential bladder cancer therapy By Investing.com - Investing.com South Africa
Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. - Quantisnow
Relmada secures exclusive license for potential bladder cancer therapy - Investing.com India
Relmada Therapeutics Announces Exclusive Licensing Agreement for NDV-01, a Novel Intravesical Therapy for Non-Muscle Invasive Bladder Cancer - Nasdaq
Relmada Therapeutics (RLMD) Licenses NDV-01 from Trigone Pharma - StreetInsider.com
Game-Changing Cancer Drug: Relmada's New Treatment Lasts 10 Days vs Hours - Stock Titan
RELMADA THERAPEUTICS Earnings Preview: Recent $RLMD Insider Trading, Hedge Fund Activity, and More - Nasdaq
Relmada Therapeutics Inc expected to post a loss of 70 cents a shareEarnings Preview - TradingView
Relmada Therapeutics (RLMD) Projected to Post Earnings on Tuesday - Defense World
Relmada seeking strategic options, stock climbs 5% - MSN
RELMADA THERAPEUTICS, INC. INVESTIGATION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Relmada Therapeutics, Inc. - ACCESS Newswire
Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight - GlobeNewswire Inc.
RLMD stock touches 52-week low at $0.28 amid market challenges - Investing.com Australia
RLMD stock touches 52-week low at $0.28 amid market challenges By Investing.com - Investing.com South Africa
A significant driver of top-line growth: Relmada Therapeutics Inc (RLMD) - SETE News
Relmada acquires new Tourette syndrome treatment asset - MSN
Relmada Therapeutics Inc [RLMD] Investment Guide: What You Need to Know - Knox Daily
RLMD stock’s current quarter earnings estimates: What analysts predict? - US Post News
Closing Strong: Relmada Therapeutics Inc (RLMD) Ends at 0.31, Down -9.62 from Last Close - The Dwinnex
Relmada Therapeutics Inc’s Shares Reel: -90.69% Quarterly Revenue Decline Amid 9.33M Market Cap - The InvestChronicle
A company insider recently bought 51,407 shares of Relmada Therapeutics Inc [RLMD]. Should You Buy? - Knox Daily
Mizuho maintains Neutral on Relmada stock, sees deal potential - MSN
The Tourette’s Deal That Came Too Late To Save Sweden’s Asarina - Insights
Relmada in-licenses Tourette syndrome drug from Asarina - The Pharma Letter
Take off with Relmada Therapeutics Inc (RLMD): Get ready for trading - SETE News
Relmada acquires Tourette’s therapy rights from Asarina - Yahoo Finance
Lipella Pharmaceuticals Inc [LIPO] Revenue clocked in at $0.48 million, up 52.46% YTD: What’s Next? - The DBT News
Relmada acquires new Tourette syndrome treatment asset By Investing.com - Investing.com Nigeria
Mizuho maintains Neutral on Relmada stock, sees deal potential By Investing.com - Investing.com Australia
3.01%
자본화:
|
볼륨(24시간):